mAbTree Biologics has signed an exclusive co-development and commercialisation partnership with Shilpa Biologicals Pvt, a fully owned subsidiary of Shilpa Medicare, for its biologic asset for immuno-oncological applications.
Vetter, a globally operating Contract Development and Manufacturing Organisation (CDMO), announces an expansion of its pharmaceutical materials warehouse in Ravensburg to meet increasing market demand and support the company's organic growth.
Almac Group has announced the official opening of a new £65m commercial manufacturing facility for Almac Pharma Services at its global headquarters in Craigavon, Northern Ireland.
Syngene International, a contract research, development, and manufacturing organisation (CRDMO), has announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
Adragos Pharma has announced the completion of a €4 million project to install and commission an advanced, cGMP-compliant liquid filling line and accompanying cartoning machine at its facility in Leipzig, Germany.
Rimkus Consulting Group has announced the acquisition of Human Factors Consulting Services, Incorporated (“HFCSI”), a highly regarded firm specialising in proactive human factors services and medical device consulting.
NewAge Industries Inc., parent company of the AdvantaPure brand of high-performance pharmaceutical and biopharmaceutical tubing and hose, proudly cut the ribbon on their new European based manufacturing site in May of 2024.
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round.
Cold Chain Technologies, a global provider of advanced thermal packaging and digital monitoring solutions for the transportation of temperature-sensitive life sciences products, has announced it has acquired Global Cold Chain Solutions.
Beckman Coulter Life Sciences in partnership with Rarity Bioscience AB offers a new approach to oncology research by extending the capabilities of flow cytometry to clinical molecular research.
Novo Holdings and TA Associates, has announced that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites.
OncoHost has announced a collaboration with Gustave Roussy, the first European cancer centre, to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy.
